Ascendis Pharma, Inc.

146 articles with Ascendis Pharma, Inc.

• Ascendis Pharma A/S Announces Second Quarter 2020 Financial Results and Business Update Conference Call on August 27

  8/13/2020

  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will hold a conference call and live webcast on Thursday, August 27, 2020 at 4:30 p.m. Eastern Time 

• Ascendis Pharma A/S Announces Upcoming Investor Presentations in August

  8/4/2020

  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will participate in two upcoming investor conferences in August. Company executives will provide a business overview and update on the company’s pipeline programs. Details Event 2020 Wedbush PacGrow Healthcare Virtual Conference Location Virtu

• Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

  7/8/2020

  Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced the pricing of its underwritten public offering of 4,225,352 American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis, at a price to the public of $142.00 per ADS.

• Ascendis Pharma A/S Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan

  7/6/2020

  – Supports the investigation of TransCon hGH for treatment of growth hormone deficiency in the pediatric population from 6 months to less than 18 years of age – – Company on track to submit European marketing application in third quarter 2020 – – No additional studies required – COPENHAGEN, Denmark, July 06, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, tod

• Ascendis Pharma A/S Announces Proposed Public Offering of ADSs - July 06, 2020

  7/6/2020

  Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, announced that it has commenced an underwritten public offering of $500,000,000 of American Depositary Shares, each of which represents one ordinary share of Ascendis.

• Ascendis Pharma A/S Announces Submission of Biologics License Application (BLA) to FDA for TransCon™ hGH in Pediatric Growth Hormone Deficiency– European marketing application on track for third quarter 2020 submission –

  6/26/2020

  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for TransCon hGH (lonapegsomatropin)

• Ascendis Pharma A/S Announces Presentation of Preclinical Data for TransCon IL-2 β/γ at AACR Virtual Annual Meeting 2020

  6/22/2020

  - In vitro data demonstrated selective binding and activation of IL-2 β/γ  receptor, associated with reduced IL-2 α   receptor binding - - Selective expansion and activation of cells in vivo consistent with receptor bias - - Long half-life and pharmacodynamic effect expected to support dosing every 3 weeks in patients - - No dose-limiting toxicities and maximum tolerated dose was not reached -

• Ascendis Pharma A/S Announces Participation in ENDO Online 2020

  6/8/2020

  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced presentations related to its rare disease endocrinology programs at ENDO Online 2020, the annual meeting of the Endocine Society, taking place June 8 - 22, 2020. “The fliGHt Trial data presented at ENDO Online demonstrate that subjects taking daily somatropin can safely switch

• Ascendis Pharma A/S Reports First Quarter 2020 Financial Results

  5/19/2020

  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced financial results for the quarter ended March 31, 2020.

• 

  BioSpace Movers & Shakers, May 15

  5/15/2020

  Pharma, biotech and life sciences companies bolster their executive teams and boards with these Movers & Shakers.

• Ascendis Pharma A/S Will Appoint Jesper Høiland as Global Chief Commercial Officer

  5/11/2020

  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will appoint Jesper Høiland as Global Chief Commercial Officer upon completion of his transition from Radius Health, Inc. "The addition of Jesper to the senior leadership team at Ascendis Pharma is a key next step in our preparation for the global launch of our

• Ascendis Pharma A/S Announces First Quarter 2020 Financial Results and Business Update Conference Call on May 19

  5/7/2020

  Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, announced that the company will hold a conference call and live webcast on Tuesday, May 19, 2020 at 4:30 p.m. Eastern Time to review its first quarter 2020 financial results and provide a business update.

• Ascendis Pharma A/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial Demonstrating Potential of TransCon™ PTH as a Replacement Therapy for Hypoparathyroidism

  4/19/2020

  PaTH Forward Trial met key objectives and showed that TransCon PTH eliminated standard of care in 82 percent of subjects within four weeks

• Ascendis Pharma A/S Receives Orphan Drug Designation for TransCon™ hGH as Treatment for Growth Hormone Deficiency in the United States

  4/15/2020

  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to TransCon hGH ( lonapegsomatropin ), as a treatment for growth hormone deficiency (GHD). TransCon hGH is an investigational long-acting prodrug of somatropin (human gro

• Ascendis Pharma A/S Reports Full-Year 2019 Financial Results

  4/1/2020

  Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, announced financial results for the full year ended December 31, 2019.

• Ascendis Pharma A/S Announces Full Year 2019 Financial Results and Business Update Conference Call on April 1

  3/25/2020

  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will hold a conference call and live webcast on Wednesday, April 1, 2020 at 4:30 p.m. Eastern Time (ET) to review its 2019 financial results and provide a business update.

• Ascendis Pharma A/S Announces Upcoming Investor Presentation in February

  2/12/2020

  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will participate in the upcoming SVB Leerink 9th Annual Global Healthcare Conference

• Ascendis Pharma A/S Provides Pipeline Update and Reviews Progress Towards Vision 3x3 at 38th Annual J.P. Morgan Healthcare Conference

  1/13/2020

  Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant unmet medical needs, will provide an outlook for 2020 and review progress towards Vision 3x3, the company’s strategic roadmap through 2025 to achieve sustainable growth at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.

• Ascendis Pharma A/S Announces Participation in 38th Annual J.P. Morgan Healthcare Conference

  1/9/2020

  Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, announced that the company will participate in the upcoming 38th Annual J.P. Morgan Healthcare Conference.

• Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results

  11/18/2019

  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced financial results for the quarter ended September 30, 2019.